Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

The stock's fall snapped a two-day winning streak.

Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...

This was the stock's second consecutive day of gains.

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.